421 Curie Boulevard
Biomedical Research Building II/III
Philadelphia, PA 19104
United States of America
The Drapkin laboratory focuses on developing a comprehensive understanding of the genetic, molecular and physiological factors that drive the development of cancer, with a special focus on gynecologic malignancies. Recent work from his group and others has implicated the fallopian tube (FT) secretory cell as the likely cell-of-origin for a majority of high-grade serous ovarian carcinomas. This new concept of ovarian tumorigenesis has been a paradigm shift in the field and the Drapkin lab has been at the forefront in developing novel experimental platforms that address the role of the FT epithelium and its susceptibility to neoplastic transformation. These platforms include genetically engineered mouse (GEM) models, fallopian tube-derived cell lines, and patient-derived tumor xenografts. Using these animal models, the Drapkin lab was the first to show that serous tubal intraepithelial carcinoma (STIC) is the precursor to high-grade serous ovarian cancer. The lab is currently focused on utilizing these models to interrogate how genetic and epigenetic alterations influence lineage dependencies, genomic instability, DNA repair, replicative stress, and metabolism. The goal is to define selective vulnerabilities that can guide novel therapeutic approaches and biomarker development.
Ben Z. Stanger, MD, PhD is the representative at this institution.